Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc > SHISEIDO WILL COMMERCIALIZE RCH-01
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by MetzGERon Oct 18, 2023 11:57am
80 Views
Post# 35689146

RE:RE:RE:RE:RE:RE:SHISEIDO WILL COMMERCIALIZE RCH-01

RE:RE:RE:RE:RE:RE:SHISEIDO WILL COMMERCIALIZE RCH-01

I don't get your Point. On the One Hand you say that Replicel has 10$/share worth if it comes to a deal on the other Hand you way that replicle
go bancrupt.

Can you please
explain what Are the Big Cost of Replicel staying Alive now as a company? They don't produce
anything. They could stop Developments of the Dermal injector. Why they should go bancrupt? Only because of the Loan of the Board members??? They really let the company go bankcrupt because they Need their loan?!
Successfull Investors like Andrew and Jamie who probably have 10-30 Mio $

i don't get it really. Where is the Risk?

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities